{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T04:09:18Z","timestamp":1780632558548,"version":"3.54.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":42,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82303229"],"award-info":[{"award-number":["82303229"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["20252BAC240444"],"award-info":[{"award-number":["20252BAC240444"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["20242BAB25508"],"award-info":[{"award-number":["20242BAB25508"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Osimertinib is the standard first-line therapy for EGFR-mutant lung adenocarcinoma; however, the inevitable development of acquired resistance leads to disease progression and treatment failure. While established resistance mechanisms primarily involve genetic alterations, stress-adaptive pathways, particularly stress granule\u2013mediated therapeutic tolerance, remain poorly understood. This study aims to elucidate the transcriptional and post-translational mechanisms governing stress granule\u2013mediated survival and their contribution to Osimertinib resistance in lung adenocarcinoma. We identify NF-\u03baB repressing factor (NKRF) as a critical suppressor of Osimertinib resistance, whose expression is markedly reduced in resistant lung adenocarcinoma cells. Restoration of NKRF significantly sensitized resistant cells to Osimertinib in vitro and inhibited tumor growth in xenograft models. Mechanistically, NKRF directly repressed transcription of the ribonucleoprotein component Small nuclear ribonucleoprotein D2 (SNRPD2), thereby constraining stress granule formation and attenuating drug tolerance. We further demonstrate that the E3 ubiquitin ligase TRIM26 interacts with NKRF and promotes its K48-linked ubiquitination at Lys411, leading to proteasomal degradation. This process sustains SNRPD2 expression and enhances stress granule assembly. Genetic depletion of TRIM26 restored NKRF stability, suppressed stress granule formation, and re-sensitized resistant tumors to Osimertinib, effects that were abrogated by concomitant NKRF silencing. Collectively, this study defines a previously unrecognized TRIM26\/NKRF\/SNRPD2 regulatory axis that integrates ubiquitin-mediated proteostasis with transcriptional control of stress granule dynamics. This work provides mechanistic insight into stress-adaptive Osimertinib resistance and identifies potential therapeutic targets for overcoming resistance in EGFR-mutant lung adenocarcinoma.<\/jats:p>","DOI":"10.1038\/s41419-026-08787-x","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T02:19:24Z","timestamp":1776997164000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["TRIM26-mediated NKRF degradation drives Osimertinib resistance through SNRPD2-dependent stress granule formation in lung adenocarcinoma"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4535-3830","authenticated-orcid":false,"given":"Tao","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Yan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Hao","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6400-6052","authenticated-orcid":false,"given":"Zhen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1156-8115","authenticated-orcid":false,"given":"Xiao-Jian","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"8787_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"8787_CR2","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1056\/NEJMe2311559","volume":"389","author":"YL Wu","year":"2023","unstructured":"Wu YL, Zhou Q. Combination therapy for EGFR-mutated lung cancer. N Engl J Med. 2023;389:2005\u20137.","journal-title":"N Engl J Med"},{"key":"8787_CR3","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/j.annonc.2024.08.2243","volume":"35","author":"S Lu","year":"2024","unstructured":"Lu S, Ahn MJ, Reungwetwattana T, Ozguroglu M, Kato T, Yang JC, et al. Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study. Ann Oncol. 2024;35:1116\u201325.","journal-title":"Ann Oncol"},{"key":"8787_CR4","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1056\/NEJMe2029532","volume":"383","author":"D Planchard","year":"2020","unstructured":"Planchard D. Adjuvant Osimertinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2020;383:1780\u20132.","journal-title":"N Engl J Med"},{"key":"8787_CR5","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","volume":"121","author":"A Leonetti","year":"2019","unstructured":"Leonetti A, Sharma S, Minari R, Perego P, Giovannetti E, Tiseo M. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer. 2019;121:725\u201337.","journal-title":"Br J Cancer"},{"key":"8787_CR6","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13045-016-0290-1","volume":"9","author":"S Wang","year":"2016","unstructured":"Wang S, Tsui ST, Liu C, Song Y, Liu D. EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer. J Hematol Oncol. 2016;9:59.","journal-title":"J Hematol Oncol"},{"key":"8787_CR7","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.21037\/tlcr-20-578","volume":"9","author":"T Yamaoka","year":"2020","unstructured":"Yamaoka T, Tsurutani J, Sagara H, Ohmori T. HER2-D16 oncogenic driver mutation confers osimertinib resistance in EGFR mutation-positive non-small cell lung cancer. Transl Lung Cancer Res. 2020;9:2178\u201383.","journal-title":"Transl Lung Cancer Res"},{"key":"8787_CR8","doi-asserted-by":"publisher","first-page":"6195","DOI":"10.1158\/1078-0432.CCR-18-1542","volume":"24","author":"X Le","year":"2018","unstructured":"Le X, Puri S, Negrao MV, Nilsson MB, Robichaux J, Boyle T, et al. Landscape of EGFR-dependent and -independent resistance mechanisms to osimertinib and continuation therapy beyond progression in EGFR-mutant NSCLC. Clin Cancer Res. 2018;24:6195\u2013203.","journal-title":"Clin Cancer Res"},{"key":"8787_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-12995-8","volume":"12","author":"Y Murakami","year":"2022","unstructured":"Murakami Y, Kusakabe D, Watari K, Kawahara A, Azuma K, Akiba J, et al. AXL\/CDCP1\/SRC axis confers acquired resistance to osimertinib in lung cancer. Sci Rep. 2022;12:8983.","journal-title":"Sci Rep"},{"key":"8787_CR10","first-page":"1854","volume":"15","author":"TV Nanthaprakash","year":"2025","unstructured":"Nanthaprakash TV, Gourlay CW, Oehme I, Garrett MD, Cinatl J, Wass Jr, et al. Phenotypic plasticity in a novel set of EGFR tyrosine kinase inhibitor-adapted non-small cell lung cancer cell lines. #N\/A. 2025;15:1854\u201373.","journal-title":"#N\/A"},{"key":"8787_CR11","volume":"16","author":"P Stegelmeier","year":"2024","unstructured":"Stegelmeier P, Dawson JA, Wallace M, Esebua M. Osimertinib resistance via histologic transformation from non-small cell lung carcinoma to carcinosarcoma. Cureus. 2024;16:e59293.","journal-title":"Cureus"},{"key":"8787_CR12","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.gendis.2021.02.005","volume":"9","author":"T Hu","year":"2022","unstructured":"Hu T, Hou W, Xiao E, Long M. Mechanism and effect of stress granule formation in cancer and its potential roles in breast cancer therapy. Genes Dis. 2022;9:659\u201367.","journal-title":"Genes Dis"},{"key":"8787_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2023.189006","volume":"1878","author":"T Li","year":"2023","unstructured":"Li T, Zeng Z, Fan C, Xiong W. Role of stress granules in tumorigenesis and cancer therapy. Biochim Biophys Acta Rev Cancer. 2023;1878:189006.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"8787_CR14","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1002\/jcp.30759","volume":"237","author":"S Mirzaei","year":"2022","unstructured":"Mirzaei S, Saghari S, Bassiri F, Raesi R, Zarrabi A, Hushmandi K, et al. NF-kappaB as a regulator of cancer metastasis and therapy response: a focus on epithelial-mesenchymal transition. J Cell Physiol. 2022;237:2770\u201395.","journal-title":"J Cell Physiol"},{"key":"8787_CR15","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41392-020-00312-6","volume":"5","author":"H Yu","year":"2020","unstructured":"Yu H, Lin L, Zhang Z, Zhang H, Hu H. Targeting NF-kappaB pathway for the therapy of diseases: mechanism and clinical study. Signal Transduct Target Ther. 2020;5:209.","journal-title":"Signal Transduct Target Ther"},{"key":"8787_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202303283","volume":"10","author":"C Guo","year":"2023","unstructured":"Guo C, Ji W, Yang W, Deng Q, Zheng T, Wang Z, et al. NKRF in cardiac fibroblasts protects against cardiac remodeling post-myocardial infarction via human antigen R. Adv Sci. 2023;10:e2303283.","journal-title":"Adv Sci"},{"key":"8787_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2023.166722","volume":"1869","author":"WF Wang","year":"2023","unstructured":"Wang WF, Zhong HJ, Cheng S, Fu D, Zhao Y, Cai HM, et al. A nuclear NKRF interacting long noncoding RNA controls EBV eradication and suppresses tumor progression in natural killer\/T-cell lymphoma. Biochim Biophys Acta Mol Basis Dis. 2023;1869:166722.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"8787_CR18","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1073\/pnas.1818539116","volume":"116","author":"XJ Chen","year":"2019","unstructured":"Chen XJ, Zhang WN, Chen B, Xi WD, Lu Y, Huang JY, et al. Homoharringtonine deregulates MYC transcriptional expression by directly binding NF-kappaB repressing factor. Proc Natl Acad Sci USA. 2019;116:2220\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8787_CR19","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1073\/pnas.1616112114","volume":"114","author":"M Coccia","year":"2017","unstructured":"Coccia M, Rossi A, Riccio A, Trotta E, Santoro MG. Human NF-kappaB repressing factor acts as a stress-regulated switch for ribosomal RNA processing and nucleolar homeostasis surveillance. Proc Natl Acad Sci USA. 2017;114:1045\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8787_CR20","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1111\/jcmm.14193","volume":"23","author":"D Sun","year":"2019","unstructured":"Sun D, Chen J, Wu W, Tang J, Luo L, Zhang K, et al. MiR-802 causes nephropathy by suppressing NF-kappaB-repressing factor in obese mice and human. J Cell Mol Med. 2019;23:2863\u201371.","journal-title":"J Cell Mol Med"},{"key":"8787_CR21","doi-asserted-by":"publisher","first-page":"522","DOI":"10.3892\/ijo.2020.5072","volume":"57","author":"X Xu","year":"2020","unstructured":"Xu X, Xia Y, Ma J, Li W, Niu N, Li X, et al. Upregulation of miRNA\u2011301a\u20113p promotes tumor progression in gastric cancer by suppressing NKRF and activating NF\u2011kappaB signaling. Int J Oncol. 2020;57:522\u201332.","journal-title":"Int J Oncol"},{"key":"8787_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14420","volume":"8","author":"XL Bian","year":"2017","unstructured":"Bian XL, Chen HZ, Yang PB, Li YP, Zhang FN, Zhang JY, et al. Nur77 suppresses hepatocellular carcinoma via switching glucose metabolism toward gluconeogenesis through attenuating phosphoenolpyruvate carboxykinase sumoylation. Nat Commun. 2017;8:14420.","journal-title":"Nat Commun"},{"key":"8787_CR23","doi-asserted-by":"publisher","first-page":"D609","DOI":"10.1093\/nar\/gkae1010","volume":"53","author":"C UniProt","year":"2025","unstructured":"UniProt C. UniProt: the universal protein knowledgebase in 2025. Nucleic Acids Res. 2025;53:D609\u2013D617.","journal-title":"Nucleic Acids Res"},{"key":"8787_CR24","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1093\/jmcb\/mjv068","volume":"8","author":"Y Ran","year":"2016","unstructured":"Ran Y, Zhang J, Liu LL, Pan ZY, Nie Y, Zhang HY, et al. Autoubiquitination of TRIM26 links TBK1 to NEMO in RLR-mediated innate antiviral immune response. J Mol Cell Biol. 2016;8:31\u201343.","journal-title":"J Mol Cell Biol"},{"key":"8787_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.611234","volume":"8","author":"Z Shao","year":"2020","unstructured":"Shao Z, Tu Z, Shi Y, Li S, Wu A, Wu Y, et al. RNA-binding protein HuR suppresses inflammation and promotes extracellular matrix homeostasis via NKRF in intervertebral disc degeneration. Front Cell Dev Biol. 2020;8:611234.","journal-title":"Front Cell Dev Biol"},{"key":"8787_CR26","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/imm.12139","volume":"140","author":"L Huang","year":"2013","unstructured":"Huang L, Liu Y, Wang L, Chen R, Ge W, Lin Z, et al. Down-regulation of miR-301a suppresses pro-inflammatory cytokines in Toll-like receptor-triggered macrophages. Immunology. 2013;140:314\u201322.","journal-title":"Immunology"},{"key":"8787_CR27","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1158\/0008-5472.CAN-21-1446","volume":"82","author":"Y Xu","year":"2022","unstructured":"Xu Y, Ren W, Li Q, Duan C, Lin X, Bi Z, et al. LncRNA Uc003xsl.1-mediated activation of the NFkappaB\/IL8 axis promotes progression of triple-negative breast cancer. Cancer Res. 2022;82:556\u201370.","journal-title":"Cancer Res"},{"key":"8787_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-55568-1","volume":"16","author":"JF Lin","year":"2025","unstructured":"Lin JF, Liu ZX, Chen DL, Huang RZ, Cao F, Yu K, et al. Nucleus-translocated GCLM promotes chemoresistance in colorectal cancer through a moonlighting function. Nat Commun. 2025;16:263.","journal-title":"Nat Commun"},{"key":"8787_CR29","doi-asserted-by":"publisher","first-page":"e42857","DOI":"10.1097\/MD.0000000000042857","volume":"104","author":"J Iovanna","year":"2025","unstructured":"Iovanna J, Estaras M, Grasso D, Fernandez Zapico ME, Neira JL, Santofimia-Castano P. Oncogenic stress response mechanisms as new therapeutic targets in cancer treatment: a review. Medicine. 2025;104:e42857.","journal-title":"Medicine"},{"key":"8787_CR30","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.tcb.2016.05.004","volume":"26","author":"DSW Protter","year":"2016","unstructured":"Protter DSW, Parker R. Principles and properties of stress granules. Trends Cell Biol. 2016;26:668\u201379.","journal-title":"Trends Cell Biol"},{"key":"8787_CR31","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2217332120","volume":"120","author":"AC Boese","year":"2023","unstructured":"Boese AC, Kang J, Hwang JS, Kim J, Eun K, Malin CM, et al. Succinyl-CoA ligase ADP-forming subunit beta promotes stress granule assembly to regulate redox and drive cancer metastasis. Proc Natl Acad Sci USA. 2023;120:e2217332120.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8787_CR32","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/s41392-024-01961-7","volume":"9","author":"C Lian","year":"2024","unstructured":"Lian C, Zhang C, Tian P, Tan Q, Wei Y, Wang Z, et al. Epigenetic reader ZMYND11 noncanonical function restricts HNRNPA1-mediated stress granule formation and oncogenic activity. Signal Transduct Target Ther. 2024;9:258.","journal-title":"Signal Transduct Target Ther"},{"key":"8787_CR33","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1038\/s43018-025-00984-5","volume":"6","author":"F Meng","year":"2025","unstructured":"Meng F, Li H, Huang Y, Wang C, Liu Y, Zhang C, et al. RIOK1 phase separation restricts PTEN translation via stress granules activating tumor growth in hepatocellular carcinoma. Nat Cancer. 2025;6:1223\u201341.","journal-title":"Nat Cancer"},{"key":"8787_CR34","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41416-020-01067-1","volume":"124","author":"J Zhao","year":"2021","unstructured":"Zhao J, Fu X, Chen H, Min L, Sun J, Yin J, et al. G3BP1 interacts with YWHAZ to regulate chemoresistance and predict adjuvant chemotherapy benefit in gastric cancer. Br J Cancer. 2021;124:425\u201336.","journal-title":"Br J Cancer"},{"key":"8787_CR35","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13045-022-01345-w","volume":"15","author":"X Wang","year":"2022","unstructured":"Wang X, Chen T, Li C, Li W, Zhou X, Li Y, et al. CircRNA-CREIT inhibits stress granule assembly and overcomes doxorubicin resistance in TNBC by destabilizing PKR. J Hematol Oncol. 2022;15:122.","journal-title":"J Hematol Oncol"},{"key":"8787_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1096-x","volume":"18","author":"Q Shi","year":"2019","unstructured":"Shi Q, Zhu Y, Ma J, Chang K, Ding D, Bai Y, et al. Prostate Cancer-associated SPOP mutations enhance cancer cell survival and docetaxel resistance by upregulating Caprin1-dependent stress granule assembly. Mol Cancer. 2019;18:170.","journal-title":"Mol Cancer"},{"key":"8787_CR37","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.cell.2015.12.038","volume":"164","author":"S Jain","year":"2016","unstructured":"Jain S, Wheeler JR, Walters RW, Agrawal A, Barsic A, Parker R. ATPase-modulated stress granules contain a diverse proteome and substructure. Cell. 2016;164:487\u201398.","journal-title":"Cell"},{"key":"8787_CR38","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.cell.2020.03.046","volume":"181","author":"P Yang","year":"2020","unstructured":"Yang P, Mathieu C, Kolaitis RM, Zhang P, Messing J, Yurtsever U, et al. G3BP1 is a tunable switch that triggers phase separation to assemble stress granules. Cell. 2020;181:325\u201345.e328.","journal-title":"Cell"},{"key":"8787_CR39","doi-asserted-by":"publisher","first-page":"12317","DOI":"10.1073\/pnas.91.25.12317","volume":"91","author":"T Lehmeier","year":"1994","unstructured":"Lehmeier T, Raker V, Hermann H, Luhrmann R. cDNA cloning of the Sm proteins D2 and D3 from human small nuclear ribonucleoproteins: evidence for a direct D1-D2 interaction. Proc Natl Acad Sci USA. 1994;91:12317\u201321.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8787_CR40","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202403387","volume":"11","author":"C Chang","year":"2024","unstructured":"Chang C, Li L, Su L, Yang F, Zha Q, Sun M, et al. Intron retention of DDX39A driven by SNRPD2 is a crucial splicing axis for oncogenic MYC\/spliceosome program in hepatocellular carcinoma. Adv Sci. 2024;11:e2403387.","journal-title":"Adv Sci"},{"key":"8787_CR41","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1007\/s11427-023-2495-x","volume":"67","author":"Z Hu","year":"2024","unstructured":"Hu Z, Li M, Chen Y, Chen L, Han Y, Chen C, et al. Disruption of PABPN1 phase separation by SNRPD2 drives colorectal cancer cell proliferation and migration through promoting alternative polyadenylation of CTNNBIP1. Sci China Life Sci. 2024;67:1212\u201325.","journal-title":"Sci China Life Sci"},{"key":"8787_CR42","doi-asserted-by":"crossref","unstructured":"Li J, Li P, Brachtlova T, van der Meulen-Muileman IH, Dekker H, Kumar VS, et al. Evaluation of spliceosome protein SmD2 as a potential target for cancer therapy. Int J Mol Sci. 2024;25.","DOI":"10.3390\/ijms252313131"},{"key":"8787_CR43","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/cr.2014.46","volume":"24","author":"Y Li","year":"2014","unstructured":"Li Y, Wu H, Wu W, Zhuo W, Liu W, Zhang Y, et al. Structural insights into the TRIM family of ubiquitin E3 ligases. Cell Res. 2014;24:762\u20135.","journal-title":"Cell Res"},{"key":"8787_CR44","doi-asserted-by":"publisher","first-page":"e1004726","DOI":"10.1371\/journal.ppat.1004726","volume":"11","author":"P Wang","year":"2015","unstructured":"Wang P, Zhao W, Zhao K, Zhang L, Gao C. TRIM26 negatively regulates interferon-beta production and antiviral response through polyubiquitination and degradation of nuclear IRF3. PLoS Path. 2015;11:e1004726.","journal-title":"PLoS Path"},{"key":"8787_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05273-w","volume":"22","author":"D Zheng","year":"2024","unstructured":"Zheng D, Ning J, Deng H, Ruan Y, Cheng F. TRIM26 inhibits clear cell renal cell carcinoma progression through destabilizing ETK and thus inactivation of AKT\/mTOR signaling. J Transl Med. 2024;22:481.","journal-title":"J Transl Med"},{"key":"8787_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-06048-9","volume":"14","author":"K Xia","year":"2023","unstructured":"Xia K, Zheng D, Wei Z, Liu W, Guo W. TRIM26 inhibited osteosarcoma progression through destabilizing RACK1 and thus inactivation of MEK\/ERK signaling. Cell Death Dis. 2023;14:529.","journal-title":"Cell Death Dis"},{"key":"8787_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05593-7","volume":"14","author":"W Wang","year":"2023","unstructured":"Wang W, Lei Y, Zhang G, Li X, Yuan J, Li T, et al. USP39 stabilizes beta-catenin by deubiquitination and suppressing E3 ligase TRIM26 pre-mRNA maturation to promote HCC progression. Cell Death Dis. 2023;14:63.","journal-title":"Cell Death Dis"},{"key":"8787_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2021.109366","volume":"337","author":"X Xie","year":"2021","unstructured":"Xie X, Li H, Pan J, Han X. Knockdown of TRIM26 inhibits the proliferation, migration and invasion of bladder cancer cells through the Akt\/GSK3beta\/beta-catenin pathway. Chem-Biol Interact. 2021;337:109366.","journal-title":"Chem-Biol Interact"},{"key":"8787_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-06222-z","volume":"14","author":"Z Wang","year":"2023","unstructured":"Wang Z, Xia Y, Wang Y, Zhu R, Li H, Liu Y, et al. The E3 ligase TRIM26 suppresses ferroptosis through catalyzing K63-linked ubiquitination of GPX4 in glioma. Cell Death Dis. 2023;14:695.","journal-title":"Cell Death Dis"},{"key":"8787_CR50","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.7150\/ijbs.81726","volume":"19","author":"Y Sun","year":"2023","unstructured":"Sun Y, Lin P, Zhou X, Ren Y, He Y, Liang J, et al. TRIM26 promotes non-small cell lung cancer survival by inducing PBX1 degradation. Int J Biol Sci. 2023;19:2803\u201316.","journal-title":"Int J Biol Sci"},{"key":"8787_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2025.102489","volume":"60","author":"NS Al-Abbas","year":"2025","unstructured":"Al-Abbas NS. TRIM26 as a dual regulator of ferroptosis and chemoresistance in gastric cancer through HSF1 ubiquitination and exosomal miR-24-3p signaling. Transl Oncol. 2025;60:102489.","journal-title":"Transl Oncol"},{"key":"8787_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2025.108438","volume":"301","author":"X Zhang","year":"2025","unstructured":"Zhang X, Zhuang M, Zhang H, Zhu Y, Yang J, Wu X, et al. Melatonin-mediated cGAS-STING signal in senescent macrophages promote TNBC chemotherapy resistance and drive the SASP. J Biol Chem. 2025;301:108438.","journal-title":"J Biol Chem"},{"key":"8787_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-08163-1","volume":"16","author":"L Zhang","year":"2025","unstructured":"Zhang L, Li Z, Wang Y, Zhang M, Chen H, Cheng Y, et al. Integrated genetic and epigenetic analysis identifies that rs939408 affects non-smoking lung adenocarcinoma risk by modulating the DNA methylation of LRRC2. Cell Death Dis. 2025;16:836.","journal-title":"Cell Death Dis"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08787-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08787-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08787-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T03:53:16Z","timestamp":1780631596000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08787-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8787"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08787-x","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"assertion":[{"value":"19 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was conducted under the approval of the Ethics Committee of the First Affiliated Hospital of Nanchang University (protocol code CDYFY-IACUC-202501GT043). All experiments were performed in accordance with the approved protocol and guidelines. Written informed consent for using clinical information and tissue samples was obtained from all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"541"}}